SCHEDULE: Armistice Capital Discloses 4.99% Stake in Kairos Pharma
Beneficial Ownership Report
Armistice Capital, LLC and Steven Boyd have disclosed a 4.99% beneficial ownership stake in Kairos Pharma, LTD. as of June 30, 2025.
Summary
- Armistice Capital, LLC and Steven Boyd collectively reported beneficial ownership of 884,938 shares of Kairos Pharma, LTD. Common Stock.
- This ownership represents 4.99% of Kairos Pharma, LTD.'s outstanding common stock.
- Armistice Capital, LLC, a Delaware entity, serves as the investment manager for Armistice Capital Master Fund Ltd., the direct holder of the shares.
- Steven Boyd, a U.S. citizen, is the managing member of Armistice Capital, LLC.
- The shares are held with shared voting and shared dispositive power by both reporting persons.
- The acquisition and holding of these securities are stated to be in the ordinary course of business, without the purpose or effect of changing or influencing the control of Kairos Pharma, LTD.
Sentiment
Score: 5
Explanation: The filing is a routine disclosure of beneficial ownership, indicating a passive investment. It does not contain information that would inherently suggest positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
This filing does not contain forward-looking statements or guidance regarding Kairos Pharma, LTD.'s future performance or operations.
Industry Context
This Schedule 13G filing indicates a passive investment by an investment management firm in a pharmaceutical company. Such disclosures are routine for institutional investors acquiring significant, but non-controlling, stakes in publicly traded companies, providing transparency to the market regarding major shareholders.
Related Party Transactions
- Armistice Capital, LLC is the investment manager of Armistice Capital Master Fund Ltd., which directly holds the shares. Steven Boyd is the managing member of Armistice Capital, LLC.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake in the company, potentially influencing market perception of institutional interest.
- Investment Professionals: Offers insight into the portfolio holdings and investment strategies of Armistice Capital, LLC.
Key Dates
| Date | Description |
|---|---|
| 06/30/2025 | Date of event which requires filing of this statement (reporting period end date for ownership). |
| 08/14/2025 | Date of filing of this statement. |
Keywords
Kairos Pharma, Armistice Capital, Steven Boyd, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Investment Management, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.